Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.06). The business had revenue of $70.90 million for the quarter, compared to analyst estimates of $73.37 million. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. Pacira Pharmaceuticals’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period last year, the firm earned $0.21 EPS. On average, analysts expect Pacira Pharmaceuticals to post $-0.96 EPS for the current fiscal year and $0.27 EPS for the next fiscal year.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) opened at 32.05 on Wednesday. Pacira Pharmaceuticals, Inc. has a 12 month low of $29.81 and a 12 month high of $58.95. The firm’s market cap is $1.29 billion. The firm’s 50-day moving average price is $35.53 and its 200-day moving average price is $41.72.

Several research firms have commented on PCRX. BMO Capital Markets decreased their price objective on shares of Pacira Pharmaceuticals from $42.00 to $40.00 and set a “market perform” rating for the company in a research note on Thursday, August 3rd. ValuEngine lowered shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. HC Wainwright set a $59.00 price objective on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. Canaccord Genuity reiterated a “buy” rating and issued a $56.00 price objective on shares of Pacira Pharmaceuticals in a research note on Monday, July 31st. Finally, Zacks Investment Research upgraded shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company. Pacira Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $50.43.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/01/pacira-pharmaceuticals-inc-pcrx-set-to-announce-quarterly-earnings-on-wednesday.html.

In related news, Director Paul J. Hastings sold 1,044 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $36.15, for a total value of $37,740.60. Following the completion of the transaction, the director now directly owns 3,518 shares in the company, valued at approximately $127,175.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David M. Stack sold 28,885 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $36.37, for a total transaction of $1,050,547.45. Following the completion of the transaction, the chief executive officer now owns 159,164 shares of the company’s stock, valued at $5,788,794.68. The disclosure for this sale can be found here. Insiders sold a total of 33,390 shares of company stock valued at $1,215,480 over the last quarter. 6.60% of the stock is owned by company insiders.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Earnings History for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.